Tibet Duo Rui Pharmaceutical Co

Tibet Duo Rui Pharmaceutical Co Intangible Assets

The Intangible Assets of Tibet Duo Rui Pharmaceutical Co (301075.SZ) as of Oct 24, 2026 is 78.48 M CNY. In the previous year, Intangible Assets was 34.19 M CNY — a change of 129.52% (higher).

Intangible Assets

78.48 MCNY

YoY

129.52%

Last updated:

Intangible Assets of Tibet Duo Rui Pharmaceutical Co is 2024 78.48 M CNY. Intangible Assets of Tibet Duo Rui Pharmaceutical Co was 2023 34.19 M CNY. It decreases by 129.52% higher compared to the previous year.

The Tibet Duo Rui Pharmaceutical Co Intangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Intangible Assets
Date
Intangible Assets
Jan 1, 2018
13.14 M CNY
Jan 1, 2019
12.77 M CNY
Jan 1, 2020
17.32 M CNY
Jan 1, 2021
16.85 M CNY
Jan 1, 2022
21.24 M CNY
Jan 1, 2023
34.19 M CNY
Jan 1, 2024
78.48 M CNY
The Tibet Duo Rui Pharmaceutical Co Intangible Assets history
YEARIntangible AssetsYoY
78.48 MCNY+129.52%
34.19 MCNY+60.98%
21.24 MCNY+26.02%
16.85 MCNY-2.66%
17.32 MCNY+35.59%
12.77 MCNY-2.84%
13.14 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Tibet Duo Rui Pharmaceutical Co Stock analysis

What does Tibet Duo Rui Pharmaceutical Co do? Tibet Duo Rui Pharmaceutical Co., Ltd. generates revenue through the research, development, manufacture, and sale of chemical preparations and their raw materials. The company's core product, sodium acetate ringer injection, is used for supplementing body fluids, regulating electrolyte balance, and correcting acidosis. Additional products include compound electrolyte injection, compound mannitol injection, and cefotaxime sodium for injection, which are sold to healthcare providers and hospitals. The firm targets the pharmaceutical market segment focused on fluid and electrolyte management and antibiotic treatments. The company's revenue streams are derived from the sale of its proprietary chemical preparations, with sodium acetate ringer injection representing a key product line. Compound electrolyte injection and compound mannitol injection cater to specific medical needs, while cefotaxime sodium for injection serves as an antibiotic solution. These products are distributed to hospitals and healthcare facilities within China's pharmaceutical distribution network. Tibet Duo Rui Pharmaceutical's business model centers on developing and commercializing specialized injectable solutions for clinical use. The firm's product portfolio addresses critical healthcare requirements, including fluid replacement, electrolyte regulation, and infection treatment. Sales are directed toward medical institutions that require these specialized pharmaceutical products for patient care. Tibet Duo Rui Pharmaceutical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Tibet Duo Rui Pharmaceutical Co stock

Intangible Assets of Tibet Duo Rui Pharmaceutical Co is 78.48 M CNY in 2024.

Intangible Assets of Tibet Duo Rui Pharmaceutical Co changed from 34.19 M CNY to 78.48 M CNY, representing a 129.52% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Intangible Assets Tibet Duo Rui Pharmaceutical Co since 2006 – with annual values, charts, and detailed analysis.

Intangible assets are non-physical assets such as patents, trademarks, copyrights, and software. They can be significant value drivers for technology and pharmaceutical companies.

Intangible Assets's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Intangible Assets's Tibet Duo Rui Pharmaceutical Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Tibet Duo Rui Pharmaceutical Co

All Key Metrics — Tibet Duo Rui Pharmaceutical Co